Search Within

Malin Lisa Hultcrantz

  1. "2019"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (5)
Groups
  1. Center for Hematologic Malignancies (18)
  2. Department of Medicine (18)
  3. Hematologic Malignancies Research (18)
  4. Hematologic Malignancies, Division of (18)
  5. Myeloma (18)
  6. Sloan Kettering Institute Postdocs (18)

More Groups

People
  1. Carl Landgren (18)
  2. Sham Mailankody (16)
  3. Neha Korde (15)
  4. Alexander Lesokhin (12)
  5. Eric Smith (12)
  6. Hani Hassoun (12)

More People

Years
  1. 2019 (18)
Publications
  1. Blood (6)
  2. Clinical Lymphoma, Myeloma and Leukemia (4)
  3. Blood Cancer Journal (2)
  4. Journal of Clinical Oncology (2)
  5. American Journal of Hematology (1)
  6. Biology of Blood and Marrow Transplantation (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. Elsevier Inc. (5)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (2)
  5. American Medical Association (1)
  6. John Wiley & Sons, Inc. (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MALDI-TOF mass spectrometry in serum for the follow-up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Meeting Abstract

    Eveillard, M.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Smith, E. L.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Korde, N.; Landgren, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft purity with novel induction regimens in multiple myeloma
    Meeting Abstract

    Bal, S.; Landau, H.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Hassoun, H.; Hultcrantz, M.; Korde, N. S.; Lesokhin, A. M.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comprehensive detection of recurring genomic abnormalities: A targeted sequencing approach for multiple myeloma
    Journal Article

    Yellapantula, V.; Hultcrantz, M.; Rustad, E. H.; Wasserman, E.; Londono, D.; Cimera, R.; Ciardiello, A.; Landau, H.; Akhlaghi, T.; Mailankody, S.; more...
    Blood Cancer Journal (2019)

    Fulltext@MSK | Save
  • Multiple myeloma and comorbidity: A population-based study
    Meeting Abstract

    Sverrisdottir, I.; Rognvaldsson, S.; Turesson, I.; Hultcrantz, M.; Bjorkholm, M.; Landgren, C. O.; Kristinsson, S.
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Depth of response and outcomes by initial therapy prior to autologous hematopoietic stem cell transplantation for multiple myeloma
    Meeting Abstract

    Shah, G.; Chung, D.; Scordo, M.; Seier, K.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lesokhin, A.; Mailankody, S.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save